TABLE 2.
Univariate analysis of DFS predicators
| Variables | SCC (n = 47) | ADC (n = 44) | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p | HR | 95% CI | p | |
| Age (years) | ||||||
| >65 vs. ≤65 | 1.56 | 0.53–4.57 | 0.42 | 1.58 | 0.69–3.65 | 0.28 |
| Gender | ||||||
| Male vs. female | 0.07 | 0.01–0.37 | 0.002 | 0.77 | 0.40–1.46 | 0.42 |
| Smoking status | ||||||
| Former/current smoker vs. never smoker | 0.38 | 0.09–1.65 | 0.2 | 0.62 | 0.32–1.20 | 0.16 |
| T stage a | ||||||
| T1–T2 vs. T3–T4 | 0.67 | 0.31–1.48 | 0.33 | 2.29 | 1.02–5.11 | 0.044 |
| N stage a | ||||||
| N2 vs. N0‐N1 | 2.12 | 0.78–5.81 | 0.14 | 1.98 | 1.00–3.91 | 0.049 |
| Stage a | ||||||
| II vs. III | 0.50 | 0.22–1.1 | 0.085 | 0.91 | 0.45–1.79 | 0.79 |
| HLA number | ||||||
| 6 vs. ≤5 | 0.95 | 0.42–2.14 | 0.98 | 1.80 | 0.82–3.95 | 0.14 |
| HLA LOH | ||||||
| Yes vs. No | 0.52 | 0.23–1.17 | 0.11 | 1.14 | 0.57–2.26 | 0.71 |
| Treatment | ||||||
| Adjuvant chemotherapy vs. none | 0.44 | 0.19–1.00 | 0.051 | 1.16 | 0.45–2.98 | 0.76 |
| Radiotherapy vs. none | 0.27 | 0.04–1.96 | 0.19 | 0.96 | 0.49–1.90 | 0.91 |
| TMB | ||||||
| ≤4 vs. >4 | 1.28 | 0.52–3.20 | 0.6 | 2.12 | 0.96–4.84 | 0.075 |
| NAL | ||||||
| ≤2 vs. >2 | 2.56 | 1.15–5.68 | 0.021 | 1.67 | 0.65–4.29 | 0.29 |
| DDR index | ||||||
| Low vs. high | 2.79 | 1.15–6.78 | 0.024 | 0.72 | 0.38–1.4 | 0.31 |
| APM status | ||||||
| Mutation vs. wild‐type | 0.85 | 0.38–1.90 | 0.69 | 1.67 | 0.69–4.00 | 0.26 |
Abbreviations: ADC, adenocarcinoma; LOH, loss of heterozygosity; NAL, neoantigen load; NSCLC, non‐small cell lung cancer; SCC, squamous cell carcinoma; TMB, tumor mutation burden.
a
Using the eighth TNM staging classification.